Laronde is advancing Endless RNA™ (eRNA), an engineered form of RNA that can be programmed to express diverse proteins inside the body. The company says eRNA is persistent, non-immunogenic, allows for repeat dosing, and offers flexibility in formulation and delivery. Laronde is scaling to support the parallel development of multiple programs across many disease areas. It intends to use newly raised capital to advance its eRNA platform and a broad pipeline of programs across a number of therapeutic categories. The company was founded in 2017 by Flagship Labs and is based in Cambridge, Mass. Key executives mentioned include CEO Diego Miralles and co-founders Avak Kahvejian and Noubar Afeyan.

Total raised

$440M

Funding rounds

1

Latest round

Series B

Latest activity

Aug 2021